Dr. Mary Claire Haver's Menopause Protocol: What It Would Cost a Non-Celebrity

Who Is Dr. Mary Claire Haver?

Dr. Mary Claire Haver is a board-certified OB-GYN based in Houston, Texas, and one of the most recognized voices in menopause medicine in the United States. She founded The Pause Life, a menopause education platform, and her 2024 book "The New Menopause" became a New York Times bestseller. She is also a certified culinary medicine specialist and has completed additional training in menopause through The Menopause Society (formerly NAMS).

She is not a celebrity in the traditional sense. She is a physician who became a public figure because she talks openly on social media and podcasts about her own menopause experience, including what she personally takes.

That transparency is rare in medicine. It is also medically consequential, because her protocol reflects current evidence-based guidelines rather than trend-driven wellness culture.

What Does Dr. Mary Claire Haver Take for Menopause?

Dr. Haver has discussed her personal hormone therapy regimen across multiple public interviews and on her social media platforms. Based on those statements, here is what she has disclosed.

Estradiol

She uses transdermal estradiol, either as a patch or a gel. This is the most studied form of estrogen for menopause. Transdermal delivery bypasses first-pass liver metabolism, which means it carries a lower risk of blood clots compared to oral estrogen. A 2016 observational study published in the BMJ found that transdermal estradiol, unlike oral estrogen, was not associated with increased venous thromboembolism risk, a finding that has shaped prescribing practice since.

Standard doses range from 0.025 mg to 0.1 mg per day for patches, applied twice weekly. Gel formulations are dosed in pumps, typically 0.75 mg per pump.

Oral Micronized Progesterone

Dr. Haver uses oral micronized progesterone (brand name Prometrium in the U.S.) rather than a synthetic progestin. This distinction matters. The WHI Memory Study and the French E3N cohort both suggested that micronized progesterone has a more favorable safety profile than synthetic progestins, particularly regarding breast cancer risk and cardiovascular effects. Any woman who has a uterus and takes systemic estrogen needs progestogen to protect the uterine lining against endometrial hyperplasia.

Women who have had a hysterectomy do not need progestogen.

Testosterone

Dr. Haver has discussed using testosterone, a point that often surprises women because testosterone is not FDA-approved for women in the United States. She typically frames this as off-label use, which is legal and clinically common. The British Menopause Society and The Menopause Society both support the use of testosterone in women for hypoactive sexual desire disorder (HSDD) when other causes have been excluded.

There is no FDA-approved testosterone product for women in the U.S., so prescriptions are off-label using male-formulated products at one-tenth the male dose, or via compounding pharmacies.

Other Elements She Mentions

She has also discussed collagen peptides, vitamin D, magnesium, omega-3 fatty acids, and resistance training as non-prescription components of her protocol. These are supplements, not medications. Their costs are real but separate from prescription hormone therapy.

The Real-World Cost Breakdown: Non-Celebrity Edition

Here is where the article gets specific. If you do not have a medical license, a large platform, or pharmaceutical industry relationships, your access pathway and costs look different. The table below reflects 2024-2025 U.S. Retail and insured pricing from publicly available pharmacy data and GoodRx estimates.

Cost With Insurance

Most commercial insurance plans cover FDA-approved hormone therapy, though coverage varies by plan tier and formulary.

| Medication | Typical Insured Copay/Month | |---|---| | Estradiol patch (generic, e.g., Mylan 0.05 mg, twice weekly) | $10-$40 | | Estradiol gel (EstroGel 0.06%, 1 pump/day) | $30-$60 | | Oral micronized progesterone 200 mg (generic Prometrium) | $10-$35 | | Testosterone cypionate (off-label, male product, 200 mg/mL vial) | $15-$40 |

Total insured estimate: $30-$80 per month for estradiol plus progesterone. Adding testosterone may bring that to $45-$120 depending on formulation and plan.

Medicare Part D covers FDA-approved HRT but coverage gaps remain common. A 2023 analysis in Menopause journal found that formulary coverage for hormone therapy varied substantially across Medicare Part D plans, with some plans excluding specific transdermal formulations entirely.

Cost Without Insurance

If you are uninsured or if your plan excludes HRT, GoodRx and Cost Plus Drugs pricing as of mid-2025 shows the following.

| Medication | Cash Price Estimate/Month | |---|---| | Generic estradiol patch 0.05 mg (8 patches) | $35-$70 | | EstroGel 0.06% (1 pump/day, 50 g tube) | $70-$120 | | Generic oral micronized progesterone 200 mg (30 capsules) | $25-$60 | | Off-label testosterone (compounded cream or gel, women's dose) | $50-$150 |

Total uninsured estimate: $80-$220 per month for standard FDA-approved estradiol plus progesterone, or $150-$400 if compounded formulations are used for all three hormones.

Compounded Versus FDA-Approved: A Cost and Safety Consideration

Dr. Haver has publicly stated a preference for FDA-approved bioidentical hormones over custom compounded preparations when possible. This aligns with The Menopause Society's 2022 position statement, which notes that FDA-approved hormone therapy products contain the same bioidentical molecules (estradiol, progesterone) as many compounded preparations but with established manufacturing standards and purity testing.

Compounded hormones are not inherently inferior, and they are sometimes the only option for women who need specific doses or delivery methods not available commercially. However, compounded products are not FDA-approved and are not held to the same batch-testing standards.

Cost-wise, compounded "troche" or pellet therapies, which are aggressively marketed at some menopause clinics, often run $200-$600 per month or more. Pellet insertion procedures add additional fees of $300-$600 per placement every three to six months. These are not the formulations Dr. Haver describes using herself.

Telehealth Access: Closing the Geography Gap

One of the most meaningful changes in menopause care since Dr. Haver rose to prominence is the expansion of telehealth prescribing. Women in rural areas or states with few menopause-trained providers can now access a prescriber via video visit.

Menopause-focused telehealth platforms typically charge:

• Initial consultation: $75-$199
• Monthly subscription (if applicable): $20-$99
• Medications: prescribed to your local pharmacy (standard costs above apply) or via the platform's pharmacy partner

The FDA's post-COVID telehealth flexibilities allowed many prescriptions, including controlled substances like testosterone, to be initiated via telehealth without an in-person visit in many states, though regulations continue to evolve at the state level.

Sex-Specific Physiology: Why These Hormones Matter for Women

Estrogen and progesterone are not optional extras. They are central to how the female body functions across multiple organ systems.

Estrogen and the Female Cardiovascular System

The Menopause Society's 2022 hormone therapy position statement states that for healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks. Estrogen loss at menopause is associated with accelerated progression of cardiovascular risk factors. The "timing hypothesis" or "window of opportunity" concept is now supported by multiple lines of evidence, including re-analyses of WHI data and the KEEPS trial (Kronos Early Estrogen Prevention Study), which found favorable cardiovascular marker profiles in recently menopausal women using low-dose oral or transdermal estradiol.

Bone Health

Women lose up to 20% of bone density in the five to seven years following menopause. Estrogen therapy is FDA-approved for the prevention of postmenopausal osteoporosis. This is not a cosmetic benefit. It is a fracture-prevention strategy with decades of supporting data.

Brain and Mood

Vasomotor symptoms (hot flashes, night sweats) affect approximately 75% of women during the menopausal transition. Sleep disruption from night sweats contributes to cognitive complaints, mood instability, and depression. Estrogen therapy reduces vasomotor symptom frequency and severity, with a Cochrane review of 24 trials finding that estrogen reduced hot flash frequency by approximately 75% compared with placebo.

PCOS and Perimenopause

Women with PCOS experience perimenopause differently. Higher baseline testosterone levels in PCOS may mask some vasomotor symptoms, but these women still lose estrogen and face metabolic and cardiovascular risks. If you have PCOS and are approaching perimenopause, the hormonal picture is more complex and warrants evaluation by a menopause-trained provider rather than a one-size approach.

Life Stage Breakdown: Who Needs What

Dr. Haver's protocol is designed for a post-menopausal or late-perimenopausal woman. Her situation is not yours if you are in a different life stage.

Reproductive Years (Under 40, Cycling Regularly)

If you have regular periods and are under 40, you are unlikely to need hormone replacement therapy. Hormonal contraception may actually manage conditions like endometriosis, PCOS-related symptoms, or heavy bleeding. If you are experiencing symptoms that feel like perimenopause before 40, ask your provider to check FSH, estradiol, and AMH to evaluate for primary ovarian insufficiency (POI), which affects approximately 1% of women under 40.

Perimenopause (Typically Mid-40s to Early 50s)

This is the most hormonally chaotic phase. Estrogen fluctuates wildly before it declines. Some women benefit from low-dose oral contraceptives during perimenopause, which simultaneously manage symptoms and provide contraception. Critically, women can still ovulate and conceive during perimenopause. HRT is not a contraceptive.

Post-Menopause (12+ Months After Last Period)

This is the stage Dr. Haver is describing. Estrogen has fallen to consistently low levels. Progesterone is minimal. Testosterone declines gradually across the late reproductive and menopausal years. This is the phase where the full HRT protocol she describes is most applicable.

Surgical Menopause

Women who undergo bilateral oophorectomy before natural menopause experience abrupt, severe estrogen loss. The ACOG Practice Bulletin on Hormone Therapy in Primary Ovarian Insufficiency recommends hormone therapy until at least age 51 (the average natural menopause age) in women with surgical or premature menopause, absent contraindications.

Pregnancy, Lactation, and Contraception: Required Reading

Hormone replacement therapy as used in menopause is contraindicated in pregnancy.

This is not a small footnote. Women in perimenopause are often surprised to learn they can still conceive. If you are taking HRT and not using contraception, and you have not yet completed 12 consecutive months without a period, pregnancy is still possible.

Estradiol in Pregnancy

Exogenous estrogen is not a safe treatment in pregnancy. Transdermal or systemic estradiol is classified as pregnancy category X in older FDA labeling conventions. The current FDA labeling system no longer uses letter categories, but the prescribing information for estradiol-containing products explicitly contraindicates use in pregnancy due to potential fetal harm, as stated in FDA-approved labeling for estradiol.

Progesterone in Pregnancy

This is the exception to the rule. Micronized progesterone (the same molecule used in HRT) is actually used in early pregnancy to support luteal phase and reduce miscarriage risk in certain clinical situations, and is FDA-approved for that use. However, the dose and formulation used in HRT are not the same as those used in early pregnancy support, and you should not self-manage this.

Testosterone in Pregnancy

Testosterone is absolutely contraindicated in pregnancy. It is teratogenic and carries serious risk of virilization of a female fetus. Women using off-label testosterone for HSDD or as part of a menopause protocol must use reliable contraception if there is any possibility of pregnancy.

Lactation

Systemic estrogen suppresses milk production and is generally avoided during breastfeeding. Local (vaginal) low-dose estrogen has minimal systemic absorption and is considered low-risk during lactation by the Infant Risk Center at Texas Tech, though it is not routinely recommended. Progesterone transfer into breast milk is limited, but data in lactating women on oral micronized progesterone is sparse. Testosterone during lactation is not studied adequately and should be avoided.

Bottom line on contraception: If you are perimenopausal and sexually active, use reliable contraception until 12 months after your final period. HRT is not contraceptive protection.

The Evidence Gap: What We Know and What We Do Not

Dr. Haver is vocal about the fact that the Women's Health Initiative (WHI), published in JAMA in 2002, scared a generation of women and their doctors away from hormone therapy based on findings that did not apply to most peri- and early-postmenopausal women. The WHI enrolled women with a mean age of 63, far older than the typical woman initiating HRT.

She is right that the timing hypothesis now has substantial support. She is also honest, in her writing and public appearances, that some questions remain open.

Women have been historically underrepresented in clinical trials across almost every disease category. In menopause specifically:

• Long-term cardiovascular outcomes for testosterone in women are not established by large randomized trials.
• Optimal testosterone dose ranges for women have not been defined by FDA-level evidence.
• Data on HRT in women with PCOS, autoimmune conditions, or a history of certain cancers is limited and largely observational.

As Dr. Haver stated in a 2023 interview with The Today Show: "We have been gaslit for decades about menopause. The WHI scared everyone, and women suffered." That framing reflects a real and documented failure of women's health research, not hyperbole.

Who This Protocol Is Right For, and Who Should Proceed Differently

Likely Appropriate

• Women 45 to 65 in perimenopause or post-menopause with bothersome vasomotor symptoms, vaginal dryness, or sleep disruption
• Women with documented estrogen-related bone loss (low bone density on DEXA) who are not taking another osteoporosis medication
• Post-menopausal women with HSDD who have discussed and been screened for off-label testosterone use with a knowledgeable provider

Requires More Caution or Specialist Review

• Women with a personal history of estrogen receptor-positive breast cancer (systemic HRT is generally contraindicated; discuss with your oncologist)
• Women with active liver disease (transdermal routes may still be acceptable)
• Women with unexplained vaginal bleeding before menopause evaluation is complete
• Women with a personal or strong family history of deep vein thrombosis or pulmonary embolism (transdermal estradiol lowers but does not eliminate risk)

Not Appropriate

• Women who are pregnant or planning pregnancy in the immediate term
• Women who are breastfeeding and considering systemic estrogen or testosterone

How to Find a Provider Who Will Actually Prescribe This

The biggest non-cost barrier for most women is finding a provider willing and able to prescribe evidence-based HRT. The Menopause Society's "Find a Provider" directory lists practitioners who have completed menopause-specific training, including NAMS Certified Menopause Practitioners (NCMP).

Telehealth menopause platforms have expanded access meaningfully. When evaluating a telehealth provider, ask:

• Does the prescriber have menopause-specific training or certification?
• Do they prescribe FDA-approved formulations as first-line before defaulting to compounded products?
• Will they coordinate with your primary OB-GYN or primary care provider?
• Do they offer DEXA referrals and baseline labs?

A provider who launches you directly to expensive compounded pellet therapy without discussing FDA-approved alternatives first is not following current evidence-based guidelines.

What Dr. Haver Herself Would Say About Cost

Dr. Haver has been consistent in messaging that hormone therapy should not be a luxury. In interviews and on her social channels, she has pointed to the availability of generic transdermal estradiol and generic oral progesterone as proof that evidence-based menopause care can be affordable. Generic estradiol patches are available through Cost Plus Drugs at prices that are significantly lower than brand-name alternatives, a point she has noted publicly.

The expensive version of menopause care, the version marketed with "bioidentical" branding, celebrity-adjacent wellness positioning, and compounded hormone pellets, is often no more effective than the generic FDA-approved version and costs substantially more.

The protocol Dr. Haver describes using herself relies on medications that, for most insured women, cost less than a monthly streaming subscription.